When is allogeneic stem cell transplant recommended for myelofibrosis?

Myelofibrosis can range from slower-moving disease to illness that threatens blood production or progresses toward acute leukaemia. A transplant replaces diseased blood-forming marrow with donor stem cells and can offer a disease-changing approach, but conditioning and immune complications make it a major treatment.

The team reviews symptoms, spleen size, blood counts, blasts, marrow results, chromosome or gene findings, transfusion needs, age, heart and lung health, other conditions, infection history, donor matching, and support at home. Medicines may be used to reduce symptoms or improve disease control before a transplant decision.

Request a transplant opinion when your haematologist identifies higher-risk features, worsening blood counts, increasing transfusion needs, or disease progression. Evaluation commonly includes organ tests, infection screening, dental review, medication review, and a discussion of fertility and caregiving.

Ask how symptom medicines, transfusions, clinical monitoring, and transplant differ for your situation. A donor search can take time, so discussing the option early may leave more choices available while your health is stable.

Call the treating team urgently for fever or chills, new breathing difficulty, chest pain, fainting, confusion, heavy bleeding, black stools, severe abdominal pain, inability to keep fluids down, or a quickly spreading rash. After transplant, new diarrhoea or jaundice also needs prompt assessment.

Ask: Which risk features apply to my myelofibrosis? What is the aim of transplant in my case? What donor sources are possible? Should I continue or change symptom-directed treatment? What complications should my caregiver watch for? What follow-up and restrictions are expected during recovery?